

AMEDISYS INC  
Form 8-K  
June 27, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**Form 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 27, 2014**  
**Commission File Number: 0-24260**

**Amedisys, Inc.**  
**(Exact Name of Registrant as specified in its Charter)**

**(State or other jurisdiction of incorporation or organization)**  
**(I.R.S. Employer Identification No.)**  
**5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816**  
**(Address of principal executive offices, including zip code)**  
**(225) 292-2031 or (800) 467-2662**  
**(Registrant's telephone number, including area code)**  
**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## **Section 7 Regulation FD**

### **Item 7.01. Regulation FD Disclosure.**

On June 27, 2014, Amedisys, Inc. (the Company ) issued a press release titled Amedisys Previews Second Quarter 2014 Results, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered filed under the Exchange Act or specifically incorporates it by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

## **Section 9 Financial Statements and Exhibits**

### **Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press Release dated June 27, 2014 titled Amedisys Previews Second Quarter 2014 Results (furnished only)

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.

By: /s/ Dale E. Redman  
Dale E. Redman  
Interim Chief Financial Officer  
DATE: June 27, 2014

**Exhibit Index**

Exhibit No.	Description
99.1	Press Release dated June 27, 2014 titled Amedisys Previews Second Quarter 2014 Results (furnished only)